[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639916":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":45,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":10,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Herlev and Gentofte Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients referred for work-up suspected of lung cancer",null,"Patients are enrolled when these are referred to the Pulmonology Department suspected of lung cancer.",[13],"Diagnostic Test: Blood tests",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Blood tests","Standard blood tests, Novel protein tumor markers specifically targeting lung cancer, Epigenetic smoking marker (AHRR methylation), Combined fragmentome, mutational and methylome analysis of cell-free tumor DNA",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Søren Egstrand, MD, PhD","CONTACT","0045 21682147","soeren.egstrand@regionh.dk",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Gentofte Hospital","RECRUITING","Gentofte Municipality","Denmark","DK",{"type":34,"coordinates":35},"Point",[36,37],12.54601,55.74903,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Søren Egstrand","MD, PhD",[46,49,51,53,55,57],{"name":47,"class":48},"NEYE Foundation","UNKNOWN",{"name":50,"class":48},"Direktør Michael Hermann Nielsens mindelegat, afd B",{"name":52,"class":48},"Toyota Foundation Denmark",{"name":54,"class":48},"Grosserer L. F. Foghts Fond Denmark",{"name":56,"class":6},"Beckett Foundation",{"name":58,"class":48},"P. A. Messerschmidt & hustrus Fond","100639916","non-invasive-malignancy-classifiers-using-blood-biomarkers-for-lung-nodule-evaluation-100639916",false,"NCT07623473","Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE","Inclusion Criteria:\n\n* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Active cancer, excluding non-melanoma skin cancer\n* Comorbidities that exclude the patient from clinical follow-up and final diagnosis",true,"ALL",{"count":70,"type":71},1800,"ESTIMATED","OBSERVATIONAL","The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.\n\nEach blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.",[75,76],"Lung Cancer (Diagnosis)","Nodule, Solitary Pulmonary",[78,79,80,81,82],"Biomarkers","Lung nodule","Fragmentomics","Methylome","Cell-free DNA","2026-05-29",{"date":85,"type":86},"2026-06-03","ACTUAL",{"date":88,"type":86},"2024-05-22",{"date":90,"type":71},"2028-02-01",{"name":5,"class":6},1]